title: Epigenetic therapy of non-small cell lung cancer using decitabine (5-aza-2'-deoxycytidine).
abstract: Epigenetic analysis shows that many genes that suppress malignancy are silenced by aberrant DNA methylation in lung cancer. Many of these genes are interesting targets for reactivation by the inhibitor of DNA methylation, decitabine (5-aza-2'-deoxycytidine, DAC). A pilot study on intense dose DAC showed promising results in patients with metastatic non-small cell lung cancer (NSCLC). However, subsequent clinical studies using low dose DAC were not very effective against NSCLC and interest in this therapy diminished. Recently, interesting responses were observed in a patient with NSCLC following treatment with a combination of the related inhibitor of DNA methylation, 5-azacytidine, and an inhibitor of histone deacetylation. This finding has generated a renewed interest in the epigenetic therapy of lung cancer. Preclinical studies indicate that DAC has remarkable chemotherapeutic potential for tumor therapy. This epigenetic agent has a delayed and prolonged epigenetic action on tumor cells. This delayed action should be taken into consideration in the design and evaluation of clinical studies on DAC. Future research should be directed at finding the optimal dose-schedule of de DAC for the treatment of NSCLC.
authors.affiliation: Département de Pharmacologie, Centre de Recherche du CHU Sainte-Justine, Université de Montréal , Montreal, QC , Canada.
authors.forename: Richard L
authors.initials: RL
authors.lastname: Momparler
keywords: chemotherapy; decitabine; epigenetics; non-small cell lung cancer
references.citation: Clin Epigenetics. 2013 Feb 01;5(1):3
references.pmid: 23369223
references.citation: Anticancer Drugs. 2002 Sep;13(8):869-74
references.pmid: 12394273
references.citation: Neoplasma. 2010;57(3):228-33
references.pmid: 20353273
references.citation: Cancer. 2006 Jul 1;107(1):116-24
references.pmid: 16721819
references.citation: Lung Cancer. 2007 Oct;58(1):131-8
references.pmid: 17606310
references.citation: Lung Cancer. 2005 Mar;47(3):309-14
references.pmid: 15713514
references.citation: J Clin Oncol. 2002 Nov 1;20(21):4285-91
references.pmid: 12409326
references.citation: Anticancer Drugs. 1997 Apr;8(4):358-68
references.pmid: 9180389
references.citation: Semin Hematol. 2005 Jul;42(3 Suppl 2):S9-16
references.pmid: 16015507
references.citation: Eur J Cancer. 2005 May;41(8):1223-36
references.pmid: 15911247
references.citation: Oncogene. 2010 Sep 16;29(37):5159-70
references.pmid: 20562917
references.citation: Cancer. 2011 Feb 1;117(3):606-17
references.pmid: 20945327
references.citation: Nat Rev Cancer. 2006 Aug;6(8):583-92
references.pmid: 16862189
references.citation: Lung Cancer. 2001 Dec;34 Suppl 4:S111-5
references.pmid: 11742714
references.citation: Cancer Epidemiol Biomarkers Prev. 2008 Mar;17(3):645-54
references.pmid: 18349282
references.citation: Semin Oncol. 2005 Oct;32(5):443-51
references.pmid: 16210084
references.citation: Cancer Lett. 2005 Jul 8;225(1):131-9
references.pmid: 15922865
references.citation: N Engl J Med. 2002 Jan 10;346(2):92-8
references.pmid: 11784875
references.citation: Clin Cancer Res. 2007 Oct 15;13(20):6087-92
references.pmid: 17947472
references.citation: BMC Cancer. 2008 May 02;8:128
references.pmid: 18454857
references.citation: Carcinogenesis. 2009 Jul;30(7):1132-8
references.pmid: 19435948
references.citation: Clin Cancer Res. 2006 Oct 1;12(19):5777-85
references.pmid: 17020984
references.citation: J Clin Oncol. 2008 Jul 20;26(21):3543-51
references.pmid: 18506025
references.citation: Cancer Res. 2004 Jul 15;64(14):4717-20
references.pmid: 15256437
references.citation: Cancer Discov. 2011 Dec;1(7):598-607
references.pmid: 22586682
references.citation: Proc Natl Acad Sci U S A. 2007 Mar 27;104(13):5527-32
references.pmid: 17369352